Patents by Inventor Bernhard Mlecnik
Bernhard Mlecnik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200248269Abstract: The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient.Type: ApplicationFiled: December 2, 2019Publication date: August 6, 2020Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: Jerome Galon, Franck Pages, Bernhard MLECNIK, Herve FRIDMAN
-
Publication number: 20200095643Abstract: The present invention relates to methods for assessing the severity of cancer by measuring the expression level of TIM-3 in a tumour sample. The present inventors have determined that the expression of TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) can be correlated with the prognosis and with the responsiveness to treatment of patients suffering from solid cancer. They have particularly demonstrated that the specific ratio of the expression level of TIM-3 to the expression level of a biomarker of the adaptive immune response within the tumour is extremely predictive of patients' survival. Thus, the present invention relates to methods for determining the prognosis patients suffering from a solid cancer by determining the ratio of the expression level of TIM-3 to the expression level of a biomarker of the adaptive immune response in a tumour tissue sample obtained from said patient. Typically, these expression levels are determined by immunohistochemistry.Type: ApplicationFiled: February 7, 2018Publication date: March 26, 2020Inventors: Jérôme GALON, Bernhard MLECNIK, Gabriela BINDEA
-
Publication number: 20190309369Abstract: The present invention relates to methods for classifying patients suffering from a solid cancer, particularly to methods for the prognosis of the survival time of a patient suffering from a solid cancer and/or to methods for assessing the responsiveness of a patient suffering from a solid cancer to antitumoral treatment. The method is based on quantifying multiple immune response markers and determining to which percentile of the distribution the values correspond when compared to a reference distribution.Type: ApplicationFiled: May 9, 2017Publication date: October 10, 2019Inventors: Jerome GALON, Bernhard MLECNIK, Franck PAGES
-
Patent number: 10317408Abstract: A method for assessment of a number or density of immune cells in tumoral tissues comprising the steps consisting in: a. providing one or more immunostained slices of tissue section obtained by an automated slide-staining system by using antibodies binding specifically to antigens (markers) expressed by immune cells. b. proceeding to digitalization of the slides of step a. by high resolution scan capture, whereby a high definition (4.6 ?m/pixel or better) digital picture of the slide to be analyzed is obtained, c. detecting the slice of tissue section on the digital picture d. analyzing the slice of tissue section for defining (i) the tumor (CT) and (ii) the invasive margin of the tumor (IM), e. providing a size reference grid with uniformly distributed units having a same surface, said grid being adapted to the size of the tumor to be analyzed, e1. checking the quality of immunostaining, f.Type: GrantFiled: June 14, 2013Date of Patent: June 11, 2019Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Descartes, Assistance Publique-Hopitaux de ParisInventors: Jerome Galon, Franck Pages, Bernhard Mlecnik
-
Publication number: 20180208995Abstract: The present invention relates to a method for predicting the outcome of a cancer. More particularly, the present invention relates to a method for predicting the outcome of a cancer in a patient comprising a step consisting of determining the expression level of a miRNA cluster in a sample obtained from said patient, wherein said miRNA cluster comprises: -miR.609 or, -miR.518c or, -miR.520f or, -miR.220a or, -miR.362 or, -miR.29a or, -miR.660 or, -miR.603 or, -miR.558 or, -miR519b or, -miR.494 or, -miR.130a or, -miR.639.Type: ApplicationFiled: January 12, 2018Publication date: July 26, 2018Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITÉ PARIS DESCARTES, ASSISTANCE PUBLIQUE -HÔPITAUX DE PARIS (APHP)Inventors: Jérôme GALON, Bernhard MLECNIK, Franck PAGES, Hervé FRIDMAN
-
Patent number: 9945861Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising the steps consisting of i) determining the density of B cells at the invasive margin of the tumor (im) in a tumor tissue sample obtained from said patient, ii) comparing said density with a predetermined reference value and iii) providing a good prognosis when the density of B cells at the invasive margin of the tumor is higher than the predetermined reference value and a poor prognosis when the density of B cells at the invasive margin of the tumor is lower than the predetermined reference value.Type: GrantFiled: January 21, 2013Date of Patent: April 17, 2018Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)Inventors: Jerome Galon, Franck Pages, Bernhard Mlecnik, Gabriela Bindea, Herve Fridman
-
Publication number: 20170175207Abstract: The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient.Type: ApplicationFiled: March 1, 2017Publication date: June 22, 2017Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: Jerome Galon, Franck Pages, Bernhard MLECNIK, Herve FRIDMAN
-
Patent number: 9645152Abstract: The present invention provides methods and kits for the prognosis of survival time of a patient suffering from a cancerous tumor. The method involves quantitating the density of Th17 cells at the center of the tumor and at the invasive margin of the tumor, where low density values at each location indicate a favourable prognosis, high values at each location indicate an unfavourable prognosis, and heterogeneous values at the two locations (one high, one low) indicate an intermediate prognosis.Type: GrantFiled: August 27, 2015Date of Patent: May 9, 2017Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes—Paris V, Assistance Publique—Hopitaux de ParisInventors: Jerome Galon, Franck Pages, Herve Fridman, Bernhard Mlecnik
-
Publication number: 20160281176Abstract: The present invention relates to a method for predicting the outcome of a cancer. More particularly, the present invention relates to a method for predicting the outcome of a cancer in a patient comprising a step consisting of determining the expression level of a miRNA cluster in a sample obtained from said patient, wherein said miRNA cluster comprises: —miR.609 or, —miR.518c or, —miR.520f or, —miR.220a or, —miR.362 or, —miR.29a or, —miR.660 or, —miR.603 or, —miR.558 or, —miR.519b or, —miR.494 or, —miR.130a or, —miR.639.Type: ApplicationFiled: May 26, 2016Publication date: September 29, 2016Applicants: Institut National de la Sante et de la Recherche M edicale (INSERM), UNIVERSITÉ PARIS DESCARTES, ASSISTANCE PUBLIQUE -HÔPITAUX DE PARIS (APHP)Inventors: Jérôme GALON, Bernhard MLECNIK, Franck PAGES, Hervé FRIDMAN
-
Publication number: 20150369811Abstract: The present invention provides methods and kits for the prognosis of survival time of a patient suffering from a cancerous tumor. The method involves quantitating the density of Th17 cells at the center of the tumor and at the invasive margin of the tumor, where low density values at each location indicate a favourable prognosis, high values at each location indicate an unfavourable prognosis, and heterogeneous values at the two locations (one high, one low) indicate an intermediate prognosis.Type: ApplicationFiled: August 27, 2015Publication date: December 24, 2015Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes - Paris V, Assistance Publique - Hopitaux de ParisInventors: Jerome GALON, Franck PAGES, Herve FRIDMAN, Bernhard MLECNIK
-
Publication number: 20150225799Abstract: The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient.Type: ApplicationFiled: April 24, 2015Publication date: August 13, 2015Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: Jerome Galon, Franck Pages, Bernhard MLECNIK, Herve FRIDMAN
-
Publication number: 20150218650Abstract: A method for screening patients with a cancer comprising i) determining in a tumor sample obtained from a patient an expression level ELA1-ELAn of one or several genes GA1-GAn representative of human adaptive immune response and an expression level ELI1-ELIn of one or several genes Gl1-GIn representative of human immunosuppressive response, ii) comparing the expression levels ELA1-ELAn and ELI1-ELIn determined at step i) with predetermined reference values ELRA1-ELRAn and ELRI1-ELRIn selected such as said predetermined reference values separate a panel of patients with a cancer into two groupings according to the expression level of said genes and to survival of patients according to Kaplan Meier curves analyses and associated logrank p values iii) concluding whether the patient has a good (level higher than the predetermined reference value) or a bad (level lower than the predetermined reference value) adaptive immune response and a good or a bad immunosuppressive response, optionally further comprising a stType: ApplicationFiled: August 5, 2013Publication date: August 6, 2015Inventors: Jerome Galon, Franck Pages, Bernhard Mlecnik, Gabriela Bindea
-
Publication number: 20150153349Abstract: A method for assessment of a number or density of immune cells in tumoral tissues comprising the steps consisting in: a. providing one or more immunostained slices of tissue section obtained by an automated slide-staining system by using antibodies binding specifically to antigens (markers) expressed by immune cells. b. proceeding to digitalisation of the slides of step a. by high resolution scan capture, whereby a high definition (4.6 ?m/pixel or better) digital picture of the slide to be analysed is obtained, c. detecting the slice of tissue section on the digital picture d. analyzing the slice of tissue section for defining (i) the tumour (CT) and (ii) the invasive margin of the tumour (IM), e. providing a size reference grid with uniformly distributed units having a same surface, said grid being adapted to the size of the tumour to be analyzed, e1. checking the quality of immunostaining, f.Type: ApplicationFiled: June 14, 2013Publication date: June 4, 2015Inventors: Jerome Galon, Franck Pages, Bernhard Mlecnik
-
Publication number: 20140363472Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising the steps consisting of i) determining the density of B cells at the invasive margin of the tumor (im) in a tumor tissue sample obtained from said patient, ii) comparing said density with a predetermined reference value and iii) providing a good prognosis when the density of B cells at the invasive margin of the tumor is higher than the predetermined reference value and a poor prognosis when the density of B cells at the invasive margin of the tumor is lower than the predetermined reference value.Type: ApplicationFiled: January 21, 2013Publication date: December 11, 2014Inventors: Jerome Galon, Franck Pages, Bernhard Mlecnik, Gabriela Bindea, Herve Fridman
-
Publication number: 20140018255Abstract: The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient.Type: ApplicationFiled: January 11, 2012Publication date: January 16, 2014Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTESInventors: Jérôme Galon, Franck Pages, Bernhard Mlecnik, Herve Fridman
-
Publication number: 20130331291Abstract: The present invention relates to a method for predicting the outcome of a cancer. More particularly, the present invention relates to a method for predicting the outcome of a cancer in a patient comprising a step consisting of determining the expression level of a miRNA cluster in a sample obtained from said patient, wherein said miRNA cluster comprises: -miR.609 or, -miR.518c or, -miR.520f or, -miR.220a or, -miR.362 or, -miR.29a or, -miR.660 or, -miR.603 or, -miR.558 or, -miR519b or, -miR.494 or, -miR.130a or, -miR.639.Type: ApplicationFiled: December 1, 2011Publication date: December 12, 2013Applicants: ASSISTANCE PUBLIQUE -HÔPITAUX DE PARIS (APHP), UNIVERSITE PARIS DESCARTESInventors: Jérõme Galon, Bernhard Mlecnik, Franck Pages, Hervé Fridman
-
Publication number: 20130203614Abstract: The present invention provides methods and kits for the prognosis of survival time of a patient suffering from a cancerous tumor. The method involves quantitating the density of Th17 cells at the center of the tumor and at the invasive margin of the tumor, where low density values at each location indicate a favourable prognosis, high values at each location indicate an unfavourable prognosis, and heterogeneous values at the two locations (one high, one low) indicate an intermediate prognosis.Type: ApplicationFiled: February 8, 2012Publication date: August 8, 2013Inventors: Jerome Galon, Franck Pages, Herve Fridman, Bernhard Mlecnik